Infections
HIV infection leads to Acquired Immune Deficiency Syndrome (AIDS), a chronic condition that weakens the immune system, predisposing individuals to opportunistic infections and malignancies. Effective antiretroviral therapy (ART) is available in Ghana to manage the disease, suppress viral replication, and improve quality of life. Early diagnosis and treatment are critical for preventing disease progression and transmission.
🦠 Overview and Pathophysiology
HIV is a retrovirus that targets CD4+ T-cells (helper T-cells), leading to progressive immunodeficiency over years. Understanding the viral lifecycle informs treatment strategies:
🔥 HIV Transmission & Risk Factors
- Virus Types: HIV-1 (global epidemic), HIV-2 (West Africa, slower progression)
- Primary Transmission: Sexual contact (80-85%), blood products, needle-sharing, mother-to-child
- Risk Factors: Unprotected sex, multiple partners, transfusion (rare in screened blood), occupational exposure
- Key Point: Body fluids with high viral load: blood, semen, vaginal fluids, breast milk
- Prevention: Condoms, PrEP (pre-exposure prophylaxis), sterile practices, PMTCT (prevention of mother-to-child transmission)
- Ghana Context: Adult prevalence ~1.7%; heterosexual transmission predominates
📈 Disease Progression & Complications
- AIDS Definition: CD4 <200 cells/µL OR specific opportunistic infections/malignancies
- Opportunistic Infections: TB (most common), PCP (Pneumocystis pneumonia), candidiasis, cryptococcal meningitis
- HIV-associated Malignancies: Kaposi sarcoma, lymphoma, cervical cancer
- Co-infections: Hepatitis B/C, TB (40-50% co-infection in Ghana), sexually transmitted infections
- Non-AIDS Conditions: Cardiovascular disease, neurocognitive decline, renal/liver disease
- Key Point: ART reduces AIDS-defining conditions by 80-90%
🎯 Clinical Memory Aid: HIV Disease Stages
- Stage 1 (Acute): Flu-like illness 2-4 weeks post-exposure (fever, rash, lymphadenopathy)
- Stage 2 (Chronic): Asymptomatic, CD4 >500, can last 8-10 years untreated
- Stage 3 (AIDS): CD4 <200 OR opportunistic infections, survival <3 years without ART
- Key Principle: "Test and Treat" - start ART regardless of CD4 count
🔍 Clinical Presentation
HIV progresses through distinct clinical stages with varying presentations. Recognizing these patterns facilitates early diagnosis:
⚡ Acute HIV Infection (2-4 weeks post-exposure)
- General: Fever (96%), fatigue (90%), rash (70%), myalgia/arthralgia (60%)
- Mucocutaneous: Oral ulcers, pharyngitis, maculopapular rash (trunk/face)
- Lymphatic: Generalized lymphadenopathy (neck, axilla, groin)
- Neurological: Headache, meningitis symptoms (aseptic meningitis)
- Gastrointestinal: Nausea, diarrhea, weight loss
- Key Point: Often misdiagnosed as flu/mononucleosis; high transmission risk due to high viral load
💀 Chronic & Advanced Disease (AIDS)
- Constitutional: Weight loss >10%, chronic diarrhea >1 month, fever >1 month
- Oral: Oropharyngeal candidiasis (thrush), oral hairy leukoplakia (EBV-related)
- Respiratory: Persistent cough (TB, PCP), dyspnea, chest pain
- Dermatological: Generalized dermatitis, recurrent herpes zoster (shingles), severe HSV
- Neurological: Headache, confusion, seizures (toxoplasmosis, cryptococcal meningitis)
- Children-specific: Failure to thrive, recurrent bacterial infections, parotitis, developmental delay
👁️ WHO Clinical Staging System (Simplified)
- Stage 1: Asymptomatic, persistent generalized lymphadenopathy CD4 usually >500 cells/µL
- Stage 2: Weight loss <10%, minor mucocutaneous manifestations, herpes zoster CD4 350-500 cells/µL
- Stage 3: Weight loss >10%, chronic diarrhea >1 month, pulmonary TB, severe bacterial infections CD4 200-350 cells/µL
- Stage 4 (AIDS): HIV wasting syndrome, PCP, toxoplasmosis, cryptosporidiosis, Kaposi sarcoma CD4 <200 cells/µL
- Key Point: Clinical staging guides urgency of ART initiation and opportunistic infection prophylaxis
⚠️ ADVANCED DISEASE INDICATORS (RED FLAGS):
- CD4 <200 cells/µL: Start PCP prophylaxis (co-trimoxazole)
- CD4 <100 cells/µL: High risk for toxoplasmosis, cryptococcal meningitis
- CD4 <50 cells/µL: Highest risk for MAC (Mycobacterium avium complex), CMV
- Slow growth in children: Height/weight <3rd percentile, developmental delay
- Screen all patients: TB (symptom screen, CXR), Hepatitis B (HBsAg), syphilis (RPR)
🧪 Diagnosis & Baseline Investigations
HIV diagnosis requires specific testing algorithms; confirmatory testing is essential before ART initiation. All diagnosed patients must be referred to accredited ART centers:
🔬 Diagnostic Testing Algorithm
- Screening test: Rapid test (Determine, OraQuick) - if positive, proceed to confirmatory
- Confirmatory test: Second rapid test from different manufacturer/principle
- Discordant results: Third tie-breaker test or Western blot (reference lab)
- HIV-1 vs HIV-2: Specific tests if HIV-2 suspected (West African origin, slower progression)
- Key Point: "Two positive rapid tests = diagnosis" in Ghanaian algorithm
📊 Baseline Monitoring Tests
- HIV viral load: Baseline, then every 6-12 months (target: undetectable <50 copies/mL)
- CD4 count: Baseline, then every 6 months until >500 for 1 year
- Drug resistance testing: If treatment failure (viral load >1000 copies/mL)
- Key Point: Viral load is PRIMARY monitoring tool; CD4 for immune recovery assessment
💉 Essential Baseline Investigations
- Co-infection screening: HBsAg, HCV antibody, syphilis (RPR), TB symptom screen
- Organ function: Creatinine (TDF nephrotoxicity), LFTs (EFV/NVP hepatotoxicity), fasting lipids
- Pregnancy test: All women of childbearing age (affects ART choice)
- Key Point: Complete baseline before ART initiation to guide regimen selection
| Test Category | Essential Tests | Purpose/Rationale |
|---|---|---|
| HIV-specific | HIV rapid tests (x2 different), Viral load, CD4 count | Diagnosis confirmation, baseline, monitoring response |
| Haematological | Full blood count, differential | Baseline anemia (AZT caution), neutropenia monitoring |
| Biochemical | Creatinine, eGFR, LFTs, fasting glucose, lipids | Organ function, ART toxicity monitoring, cardiovascular risk |
| Co-infection Screening | HBsAg, HCV Ab, syphilis (RPR), TB symptom screen ± CXR | Concurrent infection management, affects ART choice |
| Routine Examinations | Urinalysis, stool R/E (if symptomatic) | Baseline renal (proteinuria), gastrointestinal infections |
| Special Populations | Pregnancy test, Pap smear (women), drug resistance test (if indicated) | Regimen selection, cervical cancer screening, treatment failure |
🚨 CRITICAL REFERRAL INDICATIONS:
- All newly diagnosed PLHIV: Must be referred to accredited ART center (NOT managed at primary level)
- Treatment failure: Viral load >1000 copies/mL after ≥6 months ART
- Severe adverse drug reactions: Stevens-Johnson syndrome (NVP), severe hepatotoxicity, lactic acidosis
- Advanced disease: CD4 <200, opportunistic infections, malignancies
- Complex comorbidities: Renal/hepatic impairment, pregnancy, psychiatric disorders
- Pediatric HIV: All children require specialist pediatric HIV care
💊 Antiretroviral Therapy (ART)
ART is lifelong therapy combining three drugs from ≥2 classes. Ghana follows WHO guidelines with specific first-line regimens:
🎯 ART Treatment Principles
- Universal "Test and Treat": Start ART regardless of CD4 count Reduces transmission by 96%, improves survival regardless of CD4
- Combination therapy: Three drugs from ≥2 classes (prevents resistance) Never use monotherapy or dual therapy (except PMTCT in specific situations)
- Adherence critical: >95% adherence needed to prevent resistance Missed doses = viral replication = resistance mutations
- Lifelong treatment: ART suppresses but doesn't cure; stopping leads to viral rebound Immune reconstitution inflammatory syndrome (IRIS) may occur 2-8 weeks after starting
- Monitoring: Viral load primary endpoint (undetectable <50 copies/mL)
| Preferred Regimen | Components | Key Cautions/Monitoring | Clinical Pearls |
|---|---|---|---|
| TDF + 3TC/FTC + EFV (First-line PREFERRED) |
Tenofovir (TDF) + Lamivudine (3TC) or Emtricitabine (FTC) + Efavirenz (EFV) | • TDF: Renal toxicity (monitor Cr, eGFR, urine protein) • EFV: CNS effects (dizziness, vivid dreams), teratogenic (avoid in 1st trimester) |
• Once daily dosing improves adherence • EFV taken at bedtime reduces CNS side effects • Avoid in severe renal impairment (eGFR <50) |
| TDF + 3TC/FTC + NVP (Alternative) |
Tenofovir (TDF) + Lamivudine (3TC) or Emtricitabine (FTC) + Nevirapine (NVP) | • NVP: Hepatotoxicity (monitor LFTs), severe rash/SJS risk • Contraindicated: CD4 >250 (♀), >400 (♂) - hepatotoxicity risk |
• Use only if CD4 below threshold • Lead-in dose: NVP 200mg daily x14 days then BID • Stop if rash with mucosal involvement or hepatitis |
| AZT + 3TC + NVP (Alternative) |
Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP) | • AZT: Bone marrow suppression (anaemia, neutropenia) • NVP: Hepatotoxicity, rash as above |
• Avoid if Hb <8 g/dL or significant drop (>25%) • Monitor FBC monthly x3 months then 3-monthly • First-line in pregnancy (except 1st trimester) |
| AZT + 3TC + EFV (Alternative) |
Zidovudine (AZT) + Lamivudine (3TC) + Efavirenz (EFV) | • AZT: Anaemia monitoring as above • EFV: CNS effects, teratogenic |
• Good alternative if TDF contraindicated (renal) • Avoid EFV in women of childbearing potential without contraception |
| Scenario | Recommended Regimen | Key Considerations |
|---|---|---|
| Failure on TDF-based first line | AZT + 3TC/FTC + LPV/r or ATV/r | • Switch ALL 3 drugs if possible • LPV/r (Kaletra): GI intolerance, lipid elevation • ATV/r: Hyperbilirubinemia (harmless jaundice), nephrolithiasis |
| Failure on AZT-based first line | TDF + 3TC/FTC + LPV/r or ATV/r | • Consider ABC (abacavir) if both TDF and AZT contraindicated • ABC: HLA-B*5701 testing required (hypersensitivity risk) • PI-based regimens: Boosted with ritonavir (r) for better levels |
| Third-line/Advanced | Integrase inhibitor (DTG/RAL) + Optimized background | • After multiple failures, drug resistance testing essential • DTG (dolutegravir): Now preferred first-line globally • RAL (raltegravir): Twice daily, fewer drug interactions |
🔍 CRITICAL ART MANAGEMENT POINTS:
- HIV is NOT curable: ART is lifelong; stopping = viral rebound
- Adherence >95%: Missing >1 dose/week increases resistance risk
- Viral load monitoring: Primary endpoint (not CD4); target undetectable <50 copies/mL
- Adverse effect monitoring: Monthly x3 months, then 3-monthly
- Drug interactions: EFV/NVP affect CYP450 (many interactions); PIs inhibit CYP3A4
- IRIS (Immune Reconstitution Inflammatory Syndrome): Occurs 2-8 weeks after ART; treat underlying OI, continue ART
🤰 Special Populations
Tailored management approaches for vulnerable groups with specific considerations:
📉 Children & Adolescents
- Diagnosis: PCR for infants <18 months (maternal antibodies persist), rapid tests >18 months
- ART initiation: ALL children regardless of CD4/clinical stage
- Regimens: LPV/r-based preferred <3 years; ABC/3TC + EFV >3 years (weight-based dosing)
- Monitoring: Growth parameters, neurodevelopment, adherence challenges
- Key Point: Higher viral loads, faster progression than adults; need pediatric HIV specialist
👵 Other Special Considerations
- Co-infection with TB: Start ART within 2 weeks of TB treatment regardless of CD4 (except cryptococcal meningitis: wait 4-6 weeks) Key drug interaction: Rifampicin reduces PI/NNRTI levels; use EFV 800mg (not 600mg) with rifampicin
- Hepatitis B co-infection: Use TDF + 3TC/FTC (active against both HIV and HBV) Stopping these drugs may cause HBV flare; continue or substitute carefully
- Renal impairment: Avoid TDF; use AZT or ABC; dose adjust 3TC/FTC Monitor eGFR, proteinuria; refer if eGFR <50
- Elderly: More comorbidities, drug interactions, reduced renal function Simpler regimens, careful monitoring for toxicity
🩺 OPPORTUNISTIC INFECTION PROPHYLAXIS:
- CD4 <200: Co-trimoxazole (PCP, toxoplasmosis) - 960mg daily or 480mg if weight <60kg
- CD4 <100: Consider fluconazole if cryptococcal antigen positive (resource-limited settings)
- CD4 <50: Azithromycin 1200mg weekly for MAC prophylaxis (not routine in Ghana)
- Discontinuation: OI prophylaxis can stop when CD4 >200 for ≥3-6 months on ART
- TB preventive therapy: Isoniazid 300mg daily x6 months for all PLHIV without active TB
🎯 Prevention Strategies
Comprehensive prevention approaches at individual and population levels:
💊 Biomedical Prevention
- PrEP (Pre-Exposure Prophylaxis): TDF/FTC for high-risk HIV-negative individuals Reduces acquisition risk by >90% with daily adherence
- PEP (Post-Exposure Prophylaxis): 28-day ART after exposure (occupational/sexual) Start within 72 hours; sooner better (TDF/3TC + LPV/r or DTG)
- Treatment as Prevention: Undetectable = Untransmittable (U=U) ART reduces transmission risk by 96%; viral load <200 copies/mL = zero sexual transmission
- Voluntary Medical Male Circumcision: Reduces heterosexual acquisition by 60%
🛡️ Behavioral & Structural
- Condom use: Male/female condoms reduce transmission by 80-95%
- Harm reduction: Needle exchange programs for people who inject drugs
- Blood safety: Universal screening of blood products (99.9% effective in Ghana)
- Stigma reduction: Critical for testing uptake and treatment adherence
🤰 PMTCT Cascade
- Antenatal testing: Test all pregnant women at first visit and 3rd trimester
- Maternal ART: Immediate initiation regardless of CD4/gestational age
- Infant prophylaxis: NVP daily x6 weeks for all HIV-exposed infants
- Infant testing: PCR at 6 weeks, rapid test at 18 months
- Feeding counseling: Exclusive breastfeeding with maternal ART OR formula if AFASS criteria met
🔥 HIGH-YIELD: "90-90-90" Targets by 2030
- 90% of people living with HIV know their status
- 90% of diagnosed receive sustained ART
- 90% on ART achieve viral suppression
- Current Ghana status (2023): 82-74-82 (improving but gaps remain)
- Next goal: 95-95-95 by 2030 (epidemic control)
🧠 Key Pharmacologic Principles
Essential considerations for understanding and managing HIV/AIDS:
🎯 CLINICAL DECISION ALGORITHM:
- Step 1: Test all with symptoms/signs suggestive of HIV or risk factors
- Step 2: If positive: Immediate referral to ART center (NO primary care management)
- Step 3: Baseline: Viral load, CD4, co-infection screening, organ function tests
- Step 4: Start ART immediately regardless of CD4 (TDF/3TC/EFV first-line)
- Step 5: Monitor: Viral load at 6 months, then 12-monthly (target undetectable)
- Step 6: Address: Adherence (>95%), side effects, comorbidities, prevention
- Step 7: If failure (VL >1000): Resistance testing, switch to second-line
⚠️ COMMON PITFALLS TO AVOID:
- Delaying ART: Start immediately regardless of CD4 (reduces transmission/mortality)
- Poor adherence counseling: <95% adherence = resistance = treatment failure
- Missing OI prophylaxis: Co-trimoxazole for CD4 <200; isoniazid for TB prevention
- Not screening partners/children: Index testing crucial for case finding
- Stigmatizing language: Use "person living with HIV" not "AIDS patient" (unless stage 4)
- Managing at wrong level: All PLHIV need ART center management (not primary care)
- Ignoring mental health: Depression/anxiety common; affects adherence
🧭 Conclusion
HIV/AIDS remains a significant public health challenge in Ghana, but remarkable progress has been made through widespread ART access and prevention programs. The current paradigm of "Test and Treat" - initiating antiretroviral therapy immediately upon diagnosis regardless of CD4 count - has transformed HIV from a fatal diagnosis to a manageable chronic condition.
Effective management requires a lifelong commitment to combination antiretroviral therapy, with the preferred first-line regimen in Ghana being TDF + 3TC/FTC + EFV. Close monitoring of viral load (target undetectable <50 copies/mL), adherence support (>95% adherence critical), and management of side effects and comorbidities are essential for long-term success.
Special populations including children, pregnant women, and those with co-infections like TB or hepatitis require tailored approaches. Prevention strategies encompassing PrEP, PEP, PMTCT, and behavioral interventions complement treatment efforts toward achieving epidemic control.
While HIV remains incurable, with proper management people living with HIV can achieve normal life expectancy and quality of life. The U=U (Undetectable = Untransmittable) principle reinforces that effective treatment prevents sexual transmission, reducing stigma and encouraging testing and treatment uptake.
HIV management represents one of modern medicine's greatest success stories — from certain fatality to chronic manageability through scientific innovation and global solidarity. In Ghana, continued commitment to the 90-90-90 targets, stigma reduction, and equitable access to newer medications like dolutegravir will move the nation closer to epidemic control and ultimately ending AIDS as a public health threat.